Sigma Pharmaceuticals Shares Drop After Disclosure of Early Talks on Boots Sale
Sigma Pharmaceuticals shares fell sharply after the company confirmed it had engaged in early-stage discussions about the possible acquisition of Boots, a process led by private equity firm Sycamore Partners at a reported valuation near US$10 billion. Management emphasized there is no certainty a transaction will occur, but investors reacted to the…